Notably, the SARC006 trial, which tested the effect of the TOP2A inhibitors doxorubicin and etoposide in combination with ifosfamide, reported an overall response rate of 33% in the sporadic and 17% in NF1‐associated MPNST, respectively, although both were below the set target of 40% (Widemann et al., 2013). This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.